MatriTek Launches Commercial Operations at the Alexandria Center for Life Science in New York City

New York: MatriTek, Inc., a product-oriented biotechnology company specializing in tissue-specific cell culture biomaterials, announced today the launch of commercial production of novel extracellular matrix (ECM) biomaterials for biomedical research.

MatriTek’s proprietary TissueSpec™ platform technology enables scientists to culture cells in a physiologically relevant extracellular microenvironment and is coupled with the company’s core expertise in cell and tissue culture biomaterials andin-vitro models for biomedical research. MatriTek’s novel ECM biomaterials are fully customized to address research needs in cell biology, stem cell and cancer research, and regenerative medicine.

MatriTek’s cutting-edge technology was developed by a team led by Dr. Gordana Vunjak Novakovic, Mikati Foundation Professor of Biomedical Engineering and Professor of Medical Sciences at Columbia University, demonstrating the potential for a broad range of applications in stem cell research and regenerative medic

< | >